Microsatellite instability (MSI) occurs in most hereditary nonpolyposis colorectal cancers (HNPCC) and less frequently in sporadic tumors as the result of DNA mismatch repair (MMR) deficiency. Instability at coding microsatellites (cMS) in specific target genes causes frameshift mutations and functional inactivation of affected proteins, thereby providing a selective growth advantage to MMR deficient cells. At present, little is known about Selective Target Gene frameshift mutations in preneoplastic lesions. In this study, we examined 30 HNPCC-associated MSI-H colorectal adenomas of different grades of dysplasia for frameshift mutations in 26 cMS-bearing genes, which, according to our previous model, represent Selective Target genes of MSI. About 30% (8/26) of these genes showed a high mutation frequency (X50%) in colorectal adenomas, similar to the frequencies reported for colorectal carcinomas. Mutations in one gene (PTHL3) occurred significantly less frequently in MSI adenomas compared to published mutation rates in MSI carcinomas (36.0 vs 85.7%, P ¼ 0.023). Biallelic inactivation was observed in nine genes, thus emphasizing the functional impact of cMS instability on MSI tumorigenesis. Some genes showed a high frequency of frameshift mutations already at early stages of MSI colorectal tumorigenesis that increased with grade of dysplasia and transition to carcinoma. These include known Target Genes like BAX and TGFBR2, as well as three novel candidates, MACS, NDUFC2, and TAF1B. Overall, we have identified genes of potential relevance for the initiation and progression of MSI tumorigenesis, thus representing promising candidates for novel diagnostic and therapeutic approaches directed towards MMRdeficient tumors.
Introduction
Some colorectal carcinomas arise through a wellcharacterized multistep process from early dysplastic adenomas via high-grade dysplasias towards invasively growing carcinomas. This progression is accompanied by a cascade of characteristic genetic alterations (Fearon and Vogelstein, 1990) . For example, APC gene inactivation by point mutation and deletion (LOH) marks an early and supposedly initiating event promoting the development of mild-to-moderate adenoma, whereas mutation and LOH of the p53 gene is involved in the conversion of adenoma to early carcinoma. Likewise, LOH on chromosome 18q contributes to the progression of early to advanced carcinoma. This type of chromosomal instability (CIN) constitutes a molecular pathway usually found in sporadic colorectal cancer (Lengauer et al., 1997) .
A second molecular pathway is characterized by microsatellite instability (MSI) , that is, length variations of short repetitive sequences termed microsatellites (Aaltonen et al., 1993; Ionov et al., 1993; Thibodeau et al., 1993) . Although recent work indicates that there are overlaps of the CIN and MSI pathways in a noticeable number of cases (Goel et al., 2003) , the consideration of MSI and CIN as distinct molecular mechanisms of carcinogenesis seems well justified. MSI occurs in the majority of tumors of patients affected by the autosomal-dominantly inherited hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, but also arises in about 15% of sporadic malignancies of the colon and other organs (for a review see Lothe, 1997) . MSI is caused by functional inactivation of cellular DNA mismatch repair (MMR) either due to germline and somatic MMR gene mutations in the familial forms of the disease (for a review see Lynch and de la Chapelle A, 2003) or by biallelic somatic mutations and/or epigenetic mechanisms such as promoter hypermethylation of MMR genes in the sporadic neoplasms (Miyakura et al., 2001) .
HNPCC carcinogenesis like sporadic colorectal carcinogenesis proceeds through the adenoma-carcinoma sequence but at an accelerated pace, which might explain the paucity of adenomas in HNPCC individuals. The overall MSI frequency in adenomas has been reported to be much lower than in carcinomas. About 1-2% of sporadic and up to 67% of the HNPCC associated colorectal adenomas develop the MSI phenotype (Grady et al., 1998; Loukola et al., 1999; Iino et al., 2000; Sugai et al., 2003) . The occurrence of MSI was described to be present at early stages and to persist during colorectal tumor progression by some authors (Shibata et al., 1994) . Contrary results have been reported by other investigators, which might be due to the markers and reference tissues that were used (Samowitz and Slattery, 1997; Samowitz et al., 1999) . Therefore, MSI classification of MMR deficient colorectal tumors has been recommended to rely on a suggested marker panel of mono-and dinucleotide microsatellite sequences located in noncoding genomic DNA regions (Boland et al., 1998) . MSI in these noncoding microsatellites are usually expected to be irrelevant for MSI tumor biology.
In contrast, instability also affects coding region microsatellites (cMSI), which is believed to be the critical molecular mechanism required to drive the development of MSI tumors. The TGFb receptor type II (TGFBR2) gene was one of the first targets described to be affected by MSI at a coding region microsatellite. Frameshift mutations in the A 10 coding repeat of this gene have been reported to occur in up to 90% of MSI-H colorectal and 70% of MSI-H gastric cancers Myeroff et al., 1995; Parsons et al., 1995) . Several studies identified additional cancer relevant genes like IGF2R, MSH3, MSH6, BAX, CASP5, TCF4, RIZ, AIM2, ACVR2, and TAF1B, which contain cMS and are mutated in MSI-H cancers (Malkhosyan et al., 1996; Souza et al., 1996; Akiyama et al., 1997; Rampino et al., 1997; Duval et al., 1999; Schwartz Jr et al., 1999; Mori et al., 2001; Kim et al., 2002) . It is also known that different genes with cMS of identical type and length show major differences in frameshift mutation frequencies in MSI-H tumors (Duval and Hamelin 2002; Woerner et al., 2001 Woerner et al., , 2003 . In addition, MSI-H tumors of different organs displayed significant differences in frameshift mutation frequencies for a given cMS gene (Schwartz Jr et al., 1999) . These findings together with functional studies demonstrate that coding region MSI is a selective process and mutational inactivating of specific target genes and pathways should provide a growth advantage to affected cells (Furlan et al., 2002) .
Mutation frequencies of cMS-bearing genes in colorectal adenomas should allow conclusions about their role in initiation or early progression of MSI-H colon tumors. There are few previous studies investigating cMS mutations in colorectal adenomas: Mutations at the A 10 repeat of TGFBR2 have been described to occur early in MSI-H tumor development since more than 50% of adenomas analysed from HNPCC patients show mutations in TGFBR2 (Akiyama et al., 1997) . In contrast, other cMS-bearing genes like BAX were speculated rather to represent late events because frameshift mutations in the G 8 coding microsatellite of BAX were found to be frequent in carcinomas, but only rare in adenomas of HNPCC patients (Yagi et al., 1998) . A more recent study postulated that the timing of mutations at certain cMS loci was correlated with their length in the context of an increasing general level of MSI during progression of MSI-H tumors (Percesepe et al., 2000) .
So far, systematic analysis of coding microsatellitebearing genes in a large series of MSI-H colorectal adenomas is still missing. Recently, we have performed a meta-analysis of published cMS mutation frequencies in MSI colorectal cancers and proposed a model that enables the prediction of Selective Target genes (Woerner et al., 2003) . In the present study, we examined frameshift mutation profiles of 26 Selective Target genes in 30 MSI-H colorectal adenomas from verified or potential HNPCC patients and compared these results with the published mutation frequencies in MSI-H colorectal carcinomas. We also analysed the correlation of these molecular data with clinico-histopathological parameters.
Results

MSI analysis and clinico-pathological parameters of colorectal adenomas
In order to obtain a large collection of MSI-H adenomas, a series of suspicious adenomas was preselected within the framework of the German HNPCC Consortium applying criteria such as young age of diagnosis or known mutation carrier status of the patient. Using the reference marker panel recommended by the NCI/ICG-HNPCC and three additional markers, we identified 30 colorectal adenomas from 29 patients with a high level of microsatellite instability (MSI-H). Ad24 and Ad18 occurred in the same patient with a latency of 3 years. Most of the adenomas (22/30) showed instability in at least 75% of the markers analysed (Table 1) . Immunohistochemical analysis identified loss of MLH1 or MSH2 protein expression in 22/25 adenomas. In total, 14 of these adenomas occurred in HNPCC patients with verified MMR gene (Malkhosyan et al., 1996; Rampino et al., 1997; Duval et al., 1999; Schwartz Jr et al., 1999; Woerner et al., 2001) germline mutations. Histopathological examination revealed 16 adenomas with low-grade dysplasia and 14 with high-grade dysplasia (Table 2 ). These lesions comprised 23 solitary adenomas and seven with adjacent carcinoma.
cMS mutant allele frequency and profile in MSI-H adenomas
This set of 30 MSI-H adenomas was analysed for frameshift mutations in 26 genes harboring mononucleotide repeats in their coding regions. These genes were selected because they were predicted to represent Selective Target genes in MSI-H colorectal carcinomas according to our previously proposed model (Woerner et al., 2003 ) (Woerner SM, Benner A, Yuan YP, Bork P, von Knebel Doeberitz M and Gebert JF. Identifying Selective Target Genes of MSI-H Tumorigenesis). All candidate genes were found to be affected by cMS frameshift mutations. The observed cMS mutation frequencies in MSI-H adenomas ranged from 8.7% (RGS12) to 72.0% (TGFBR2) ( Table 3 ) with 30% (8/26) of target genes showing cMS mutation frequencies of at least 50%. In 31 normal mucosae and six non-MSI-H adenomas, which served as control samples such mutations, were rarely observed amounting to a total of 35 mutations, 10 of them occurring in two mucosa samples and five of them occurring in the six non-MSI-H adenoma samples. The difference between the mutation rate distribution in MSI-H adenomas vs non-MSI-H control samples was highly significant (Po0.001, bootstrap test).
When we examined the distribution of mutant alleles in more detail, 259 frameshift events were observed in a total of 656 analyses with multiple alleles (i.e. À2, À1, wt) of a given gene occurring in the same sample (Table 4 ). In most cases (397/656), only wild-type alleles were observed. However, a mixed pattern comprised of both frameshift and retained wild-type allele was detected in 245/259 analyses. Moreover, frameshift mutant alleles in the absence of wild-type alleles, which is indicative of biallelic inactivation, occurred in 14/259 cases affecting nine genes (ACVR2, AIM2, CASP5, ELAVL3, FLJ11383, MACS, NDUFC2, PTHL3, TEAD2). In 124 cases, allele status could not be determined because of limited amounts or poor quality of DNA, or lack of corresponding normal tissue in case of polymorphic alleles (Axin2). The majority of these failures (74/124) could be assigned to five samples (Ad10, Ad13, Ad16, Ad19, Ad29). The most common type of allelic shifts were deletion mutations (216/259) usually affecting one or two nucleotides (À2À1wt, À2wt, À1wt, or À1), whereas plus shifts (wt þ 1, À1wt þ 1) were observed less frequently (43/259). They were found in different adenoma tissues and different genes, thus excluding tissue or repeat specificity. Adenomas occurred in the same patient with a latency of 3 years Associated CA: carcinoma in direct proximity to adenoma Deletion mutations shifting the reading frame by two nucleotides were identified in 46/656 cases, with 23/46 events occurring in three genes (HT001 (n ¼ 11), ACVR2 (n ¼ 7), and TAF1B (n ¼ 5)).
When we examined the cMS mutation pattern of Ad18 (Colon descendens) and Ad24 (Colon ascendens), which were obtained from the same patient, we found that both adenomas showed high levels of instability in the coding repeats analysed (Ad24: 10/26, and Ad18: 14/ 26 respectively). However, the overlap of affected genes was comparably low (n ¼ 4: DD5, SEC63L, SLC23A1, TGFBR2). At these four cMS, the mutational events were of similar type in three genes (DD5, SEC63L, TGFBR2), and divergent in one gene (SLC23A1 ,  Table 4) .
Overall, high level of coding repeat instability affecting at least 30% of cMS gene sequences was found in 20 (67%) adenomas. These results demonstrate manifestation of the MSI phenotype in a variety of different cMS target genes, some of them showing biallelic inactivation already during development of MSI adenomas.
Comparison of cMS frameshift mutation profile between MSI-H colorectal adenomas and carcinomas
In order to relate this frameshift mutation pattern to MSI tumorigenesis we compared -on a gene-specific basis -the cMS mutation frequencies between MSI-H adenomas and MSI-H carcinomas. The carcinoma data were compiled from a survey of published MS mutation frequencies (December 2003) applying stringent selection criteria (Woerner SM, Benner A, Yuan YP, Bork P, von Knebel Doeberitz M and Gebert JF. Identifying Selective Target Genes of MSI-H Tumorigenesis). Mutation frequencies of 11 cMS-bearing genes approached (ACVR2, AIM2, Axin2, DD5, TGFBR2) or even slightly exceeded (BAX, ELAVL3, NDUFC2, SLC23A1, SLC4A3, TEAD2) the mutation frequencies reported for MSI-H colorectal carcinomas (Table 3) . The remaining genes showed a noticeably lower mutation rate in adenomas (>10% difference) than in carcinomas. Univariate analysis revealed significantly lower mutation frequencies in adenomas for five genes (AC1, CASP5, FLJ11383, MSH3, PTHL3). For PTHL3, this difference remained significant after multivariate analysis (36 vs 86%, P ¼ 0.023, Table 3 ). This suggests that cMS mutations in PTHL3 appear to mark a rather late step in the MSI adenoma-carcinoma sequence.
Correlation of cMS frameshift mutation profile with clinico-pathological features
In order to determine whether the cMS mutational profile correlated with grade of dysplasia, we compared 16 MSI-H low-and 14 high-grade dysplastic adenomas (Table 5a ). Adenomas with low-grade dysplasia showed fewer mutational events (120 events in 337 analyses) than high-grade dysplastic adenomas (139 events in 319 analyses). Some genes like TCF4, TGFBR2, RGS12, HT001, SLC23A1, MACS, and NDUFC2 tended to be Allele nomenclature: wild type (wt). One or two mononucleotide deletions (À1, À2), one mononucleotide insertion (+1), analysis failed or not evaluable (0). a Adenomas occurred in the same patient with a latency of 3 years Coding microsatellite instability in colon adenomas SM Woerner et al mutated at higher frequency in the group of high-grade dysplastic lesions, whereas FLJ11383 was more frequently affected by mutations in adenomas with lowgrade dysplasia (P ¼ 0.043, univariate analysis). Subsequently, adenomas were stratified for the presence (7/30) or absence (23/30) of an associated carcinoma. Overall mutation frequency was higher in the group of adenomas, which had developed into invasively growing carcinomas (73 events in 149 analyses) when compared to solitary adenomatous lesions (186 events in 507 analyses) (Table 5b ). In particular, BAX and NDUFC2 showed significantly higher mutation rates in carcinoma-associated adenomas (univariate analysis). Six genes (BAX, MACS, NDUFC2, TAF1B, TCF4, TGFBR2) displayed an increased mutation frequency (>10% difference) in high-grade dysplastic as well as in carcinoma-associated adenomas. A direct correlation between grade of dysplasia and carcinoma association Table 2 ).
Discussion
The present study was initiated as a first step to address three major questions: What is the cMS frameshift mutation profile of Selective Target genes in MSI-H colorectal adenomas? Does the cMS frameshift mutation profile differ significantly between MSI-H colorectal adenomas and carcinomas? Can we detect any obvious correlation between cMS mutation profile and clinicopathological features of MSI adenomatous lesions? Studies examining MSI-H colon adenomas are usually hampered by two limitations: MSI occurs less frequently in colorectal adenomas compared to carcinomas, and often only very small amounts of DNA are obtained from microdissected dysplastic crypts. As part of our multicenter screening for sporadic and hereditary MSI tumors, we identified 30 MSI-H colorectal adenomas amenable to frameshift mutation analysis in coding region microsatellites. The 26 cMS-bearing genes examined for this analysis were chosen because they were predicted to represent Selective Targets of MSI in colorectal carcinomas, according to our previously established regression model (Woerner et al., 2003) (Woerner SM, Benner A, Yuan YP, Bork P, von Knebel Doeberitz M and Gebert JF. Identifying Selective Target Genes of MSI-H Tumorigenesis). They include the well known and characterized TGFBR2 and BAX genes as well as other genes already considered to be associated with MSI carcinogenesis (CASP5, MSH3, MSH6). However, our panel of cMS-bearing genes also comprised 21 genes, which have never been analysed for frameshift mutations in MSI-H adenomas.
Notably, we found about 30% of the cMS genes to be mutated in at least 50% of adenomas. Several of the genes investigated in these adenomas either approached (ACVR2, AIM2, Axin2, DD5, TGFBR2) or even slightly exceeded (BAX, ELAVL3, NDUFC2, SLC23A1, SLC4A3, and TEAD2) the cMS frameshift mutation frequencies reported for MSI-H colorectal carcinomas. These results clearly indicate that instability affecting coding microsatellites is a common event already in colorectal adenomas, thus pointing to a significant contribution of cMS mutations to the progress of MSI colorectal tumorigenesis. Moreover, this suggests that some genes previously predicted to be relevant for MSI carcinogenesis (Woerner et al., 2003) already appear to be involved in development of MSI-H adenomas. This hypothesis is supported by our finding that at least nine of the analysed genes (ACVR2, AIM2, CASP5, ELAVL3, FLJ11383, MACS, NDUFC2, PTHL3, TEAD2) showed biallelic inactivation, a criterion arguing in favor of functional relevance (Boland et al., 1998) .
Mutations affecting cMS were significantly more frequent in MSI-H colorectal adenomas when compared to non-MSI-H adenomas or normal colonic epithelial tissue. This indicates that cMS mutations are a phenomenon that is specific for MSI tumorigenesis; however, incidental cMS mutations were also observed in adenomas typed as non-MSI-H and, interestingly, in DNA derived from histologically normal colonic epithelium. Similar observations were also reported by others (Duval et al., 2001) , particularly in HNPCC germline mutation carriers . The significance of these findings is not clear at present; they may either indicate occasional loss of DNA MMR function in some nontumorous cells or the consequence of MMR haploinsufficiency (Alazzouzi et al., 2005) .
Two of the most intensively studied genes, TGFBR2 and BAX, were found to be affected in 72 and 50% of colorectal adenomas in the present study, respectively. TGFBR2 mutation frequency was thus higher than the mutation rates in MSI adenomas published previously (0-57%) (Akiyama et al., 1997) . The comparably lower mutation rates of TGFBR2 reported by other investigators can be explained most likely by two reasons: the low number of adenomas analysed, and the variable marker panels used to determine MSI, which often was different from the recommended Bethesda marker panel (Boland et al., 1998) , thus leading to the inclusion of MSI-L samples. Similarly, lower mutation frequencies for BAX reported by Yagi et al. (1998) are attributable at least in part to sample collection.
In multivariate analysis, one gene (PTHL3) showed significantly lower mutation rates in colorectal adenomas compared to carcinomas (36 vs 86%, adjusted P ¼ 0.023). Four genes (AC1, CASP5, FLJ11383, MSH3) showed a significant difference only in univariate analysis. Different explanations can be envisioned for the molecular basis of the observed lower mutation frequency of some genes in adenomas compared to carcinomas. One interpretation is that mutations in some of these genes may be neutral mutations strongly dependent on mitotic history, and hence, due to a shorter mitotic history, adenomas would show a lower mutation frequency in these genes than carcinomas. Alternatively, in some cases, mutations might contribute to the adenoma-carcinoma transition and thus be selected for at this stage, leading to a higher frequency observed in carcinomas than in adenomas. The PTHL3 gene might represent one such example because it is the only case where adjusted P-value remained statistically significant. However, lineal follow-up studies of the same tumor and functional analyses are required to verify this conclusion.
Apart from the direct comparison of cMS mutation frequencies between adenomas and carcinomas, our data also allowed correlations with histological features of the adenomas. Stratification for grade of dysplasia or presence of an associated carcinoma revealed more cMS mutational events in high-grade dysplastic adenomas compared to low-grade adenomas. Accordingly, the overall mutation frequency of MSI-H adenomas in the 26 genes analysed positively correlated with dysplastic grade. In addition, the number of mutational events in adenomas associated with an adjacent carcinoma was higher compared to solitary adenomas. Even though subgroup analyses in part refer to groups of small sample size and thus have to be interpreted carefully, some genes became conspicuous with significant differences between the subgroups in univariate analysis (BAX and NDUFC2). It is tempting to speculate that these genes might be involved and thus selected for during the initiation of early stage MSI adenomas. However, analyses of a larger set of samples and functional studies are required to verify this conclusion.
Taking into account the precautions mentioned above, one might speculate that genes whose cMS frameshift mutations provide a growth advantage to MMR-deficient cells along the MSI adenoma-carcinoma pathway might fulfill the following criteria: (i) high mutation frequency in low-grade adenomas, (ii) increased mutation frequency with progression towards high-grade adenomas, and (iii) a higher mutation frequency in adenomas that have developed into invasive carcinomas compared to solitary adenomatous lesions. Genes matching these criteria include the wellknown Target genes, TGFBR2 and BAX, which corroborate the validity of the present analysis, as well as MACS, TAF1B, and NDUFC2, which have never been examined before in the MSI-H adenomas. In colorectal carcinomas, a high frequency of cMS frameshift mutations has previously been reported for these genes (Mori et al., 2001; Kim et al., 2002; Li et al., 2003; Woerner et al., 2003) . MACS, the most prominent cellular substrate for protein kinase C, is thought to be involved in cell motility, phagocytosis, membrane trafficking, and mitogenesis (Blackshear 1993; Li et al., 2001) . Kim et al. (2002) speculated that the inactivation of MACS is associated with tumorigenesis. The TAF1B protein is known to constitute an essential part of the RNA polymerase I cofactor SL1 (Comai et al., 1994) . Mutations in TAF1B disrupt SL1 complex formation and lead to a reduced transcription of rRNA genes. NDUFC2 is a subunit of the enzyme NADH-ubiquinone oxidoreductase (Loeffen et al., 1998) , and mutational inactivation of NDUFC2 might be linked to tumorigenesis by apoptosis inhibition (Leist et al., 1997; Kroemer et al., 1998) . However, there is no functional evidence for any role of these proteins in colorectal carcinogenesis.
In summary, the study represents the first systematic analysis of frameshift mutations affecting Selective Target genes in a large set of MSI-H colorectal adenomas. Our results indicate that in these early lesions coding MSI has a high prevalence, increasing with grade of dysplasia. Based on the cMS mutation profile, we propose a set of novel candidate genes that are potentially relevant for early MSI-H colorectal tumorigenesis. These findings may have clinical implications for future diagnostic and therapeutic strategies applicable to MSI-H colorectal tumors.
Materials and methods
Tumor specimens
Colon adenoma tissues and matched normal mucosa were collected by the Institute of Pathology (Klinikum Kassel), the Department of Pathology (University Hospital Bonn), the Department of Surgery (University of Technology, Munich), and the Institute of Molecular Pathology (University of Heidelberg) as members of the German HNPCC Consortium. Most patients recruited to this national multicenter study fulfilled the Bethesda or Amsterdam Criteria (Rodriguez-Bigas et al., 1997; Vasen et al., 1999) . Informed consent was obtained from the patients entering this study. Histopathological classification of dysplastic adenomas was performed independently by two pathologists.
Microdissection of formalin-fixed and paraffin-embedded tissue was carried out as described (Sutter et al., 1999) . The Qiamp Tissue Kit (Qiagen, Hilden, Germany) was used for extraction of genomic DNA from microdissected tissues according to the manufacturer's instructions.
MSI was determined using the NCI ICG-HNPCC microsatellite reference marker panel (Boland et al., 1998) . The adenomatous tissues were also examined by three additional microsatellite markers including BAT40, APdelta3 (Ionov et al., 1993 ) and a T 25 repeat tract (Findeisen P, Kloor M, unpublished results).
Coding MSI analysis
Primers were designed with primer3 software (Whitehead Institute for Biomedical Research, http://www.broad.mit.edu/ genome_software/other/primer3.html) and selected to generate short amplicons (100 bp) in order to assure robust PCR amplification from archival tissues (Table 1) . One oligonucleotide of each primer set carried a fluorescent label. PCR was performed in a total volume of 5 ml containing 0.5 ml 10 Â reaction buffer (Invitrogen, Karlsruhe, Germany), 1.5 mM MgCl 2 , 200 mM dNTPs, 0.3 mM of each primer, and 0.1 U Taq DNA polymerase (Invitrogen), and 10 ng of genomic DNA, using the following conditions: initial denaturation at 941C for 4 min, followed by 35 cycles of denaturation at 941C for 30 s, annealing at 581C for 45 s, and primer extension at 721C for 30 s. The final extension step was carried out at 721C for 6 min. PCR fragments were separated on an ABI3100 genetic analyzer (Applied Biosystems, Darmstadt, Germany). Raw data were analysed with Genescan analysis software (Applied Biosystems, Darmstadt, Germany). Instability was scored, if novel peaks were obtained in tumor compared to normal tissue, or if the ratio of peak areas of corresponding peaks in tumor and normal tissue revealed values p0.5 or X2 (Woerner et al., 2001) .
Immunohistochemical analysis
Freshly cut paraffin sections (2 mm) were deparaffinized in xylene, re-hydrated in graded alcohols and washed in TRIS buffer. Microwave treatment was performed for epitope retrieval (600 W, 15 min in prewarmed 10 mM sodium citrate buffer, pH 6). Primary antibodies were added (dilution: MSH2 1 : 50, MLH1 1 : 75) and slides were incubated overnight at 41C. Slides were then processed on an immunostainer (TechMate 500, Dako, Hamburg, Germany). For signal detection the avidin-biotin complex (ABC) method and the AEC chromogen was used. Loss or reduction of MMR protein expression was scored if immunostaining was absent in tumor cell nuclei compared to normal mucosa, stroma or lymphocytes. After counterstaining with hematoxylin all sections were examined by two pathologists in a blinded fashion.
Statistical analysis
For the gene wise comparison of mutation rates we computed unadjusted and adjusted P-values using Fisher's exact test. Adjusted P-values were computed using Holm's step-down multiple testing procedure (Holm, 1979) . This procedure provides strong control for the family-wise error rate (FWER). A result was judged as statistically significant at a P-value not larger than 5%. Correlations between grade of dysplasia and carcinoma association were estimated by Pearson's correlation coefficient. All statistical analyses were performed using R, version 1.9.1 (R Development Core Team 2004).
